The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
暂无分享,去创建一个
O. Mor | E. Mendelson | M. Mandelboim | G. Regev-Yochay | N. Atari | N. Zuckerman | S. alroy-Preis | Y. Lustig | Chen Weiner | N. Rainy | Reut Sorek-Abramovich | Patricia Benveniste-Levkovitz | E. Bucris | I. Nemet | L. Kliker | Dana Bar Ilan | Ramzia Abu Hamed | Miranda Geva | A. Bar‐Chaim | Ofra Hevkin | Nir Rainy
[1] Wasim Abdool Karim,et al. Rapid replacement of the Beta variant by the Delta variant in South Africa , 2021, medRxiv.
[2] A. Ryo,et al. Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant , 2021, medRxiv.
[3] Jorge Fernández,et al. Neutralization of alpha, gamma, and D614G SARS‐CoV‐2 variants by CoronaVac vaccine‐induced antibodies , 2021, Journal of medical virology.
[4] L. Solari,et al. Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS‐COV‐2 lineage in Peru despite circulation of variants of concern , 2021, Journal of medical virology.
[5] O. Pybus,et al. Viral infection and Transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant , 2021, medRxiv.
[6] P. Romero,et al. The Emergence of Sars-CoV-2 Variant Lambda (C.37) in South America , 2021, medRxiv.
[7] Mehrdad Mohammadi,et al. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines , 2021, The Brazilian Journal of Infectious Diseases.
[8] O. Mor,et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[9] P. Dormitzer,et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants , 2021, The New England journal of medicine.
[10] D. Swerdlow,et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.
[11] E. Mendelson,et al. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 , 2021, The New England journal of medicine.
[12] D. Stuart,et al. Antibody evasion by the P.1 strain of SARS-CoV-2 , 2021, Cell.
[13] M. Hernán,et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.
[14] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[15] Philip R. O. Payne,et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment , 2020, J. Am. Medical Informatics Assoc..
[16] Trevor Bedford,et al. Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.